Interactions on record — worth a quick check against your medications. Based on 3 of 7 ingredients. Check your meds →
Dietary supplement

Cholesterol Shield Ingredients & Drug Interactions

by Nature's Way

Tablet Or Pill Category: Other Combinations
Most serious interaction: Moderate
The interaction bottom line Most serious interaction: Moderate

Cholesterol Shield is a dietary supplement by Nature's Way with 7 active ingredients. Its ingredients are commonly taken for replacing fluids and electrolytes, preventing dehydration during exercise or illness, treating low blood sodium (under medical care).Based on those ingredients, 322 medications have a known interaction with it, the most serious rated moderate. The ingredients most likely to interact are Sodium, Pantesin Pantethine. Use the checker below to test your specific medication, or read the full HelloPharmacist Interaction Report.

HelloPharmacist Scorecard of Cholesterol Shield by Nature's Way

Our pharmacy team’s full take, with four database checks built into the cards below — a summary of what is known, not a grade of the product itself.

From our pharmacy team — supplement deep dive

What’s inside

Low disclosure
Ingredient Transparency · database check
Low

Most active ingredients don't disclose an individual amount — you can't tell how much of each you're getting.

Why this rating?
  • The label discloses an exact amount for 2 of its 7 active ingredients.
  • “Proprietary Phytosterol Blend” is a proprietary blend — the label gives one combined amount (400 mg) without saying how much of each component you get.

Cholesterol Shield contains 7 active ingredients: Sodium, Stigmasterol, Brassicasterol, Beta Sitosterol, Campesterol, Pantesin Pantethine, and a Proprietary Phytosterol Blend. These are plant-derived compounds (phytosterols and pantethine) combined with sodium.

The inactive ingredients — cellulose, sodium croscarmellose, silica, magnesium stearate, hypromellose, and glycerin — are typical tablet excipients used for binding, flow, and coating.

Does it work?

Moderate evidence
Evidence for Intended Use · database check
By FDA rules, dietary supplements can’t claim to treat, cure, or prevent disease — so labels speak in careful marketing language. We discern each product’s intended use from its name, label claims, and label statements, then grade the clinical evidence for that use. How these ratings are computed
Moderate

Some clinical evidence supports this product's ingredients for its stated purpose, but it isn't conclusive.

Why this rating?
  • The label markets this product for: Support healthy cholesterol levels.
  • We looked for evidence on: Familial hypercholesterolemia, Hyperlipidemia, Hyperlipoproteinemia, Coronary heart disease (CHD), Dyslipidemia, LDL cholesterol reduction — and 1 related terms.
  • The strongest evidence on file: Beta-sitosterol is rated "Possibly Effective" for Coronary heart disease (CHD) (Natural Medicines).
  • Also on file: Beta-sitosterol is rated "Possibly Effective" for Familial hypercholesterolemia.
  • Also on file: Pantethine is rated "Possibly Effective" for Hyperlipoproteinemia.

Beta-sitosterol in this product is likely effective for benign prostatic hyperplasia (enlarged prostate) and possibly effective for familial hypercholesterolemia and coronary heart disease. Pantethine is possibly effective for hyperlipoproteinemia.

Sodium has sufficient evidence to be rated likely effective for cystic fibrosis and possibly effective for amphotericin B nephrotoxicity (kidney damage caused by an antifungal drug), though that use is niche. For the other active ingredients — Stigmasterol, Brassicasterol, Campesterol, and the proprietary blend — we hold no effectiveness data.

The evidence, ingredient by ingredient Sodium Pantethine Beta-sitosterol

How safe is it?

Well-documented data
Safety Information · database check
Well characterized

Adverse-effect, pregnancy, and general safety data are on file for most of these ingredients.

Why this rating?
  • We hold adverse-effect (side-effect) data for 3 of the 3 matched ingredients.
  • Pregnancy & breastfeeding safety ratings cover 3 of 3.
  • General safety write-ups exist for 3 of 3.
  • Remember: this measures how much safety information exists. Thin data is not the same as being safe.

Beta-sitosterol is generally well tolerated for short-term use in most adults, though constipation, diarrhea, gas, indigestion, and nausea can occur; it may worsen acne. Pantethine is generally well tolerated, with mild gastrointestinal side effects (nausea, vomiting, diarrhea, bloating, flatulence) being most common, and rare itching reported.

Sodium in normal dietary amounts is fine, but this product is a sodium supplement — too much sodium is linked to high blood pressure, heart strain, and kidney disease. Avoid supplemental sodium without medical advice.

Pregnancy and breastfeeding data are insufficient for pantethine, and there isn't enough safety data for beta-sitosterol during pregnancy or breastfeeding, so both should be avoided unless your doctor advises otherwise. Sodium's pregnancy and lactation safety data show mixed ratings — check with your doctor before taking this product if you're pregnant or nursing.

Side effects, ingredient by ingredient Sodium Pantethine Beta-sitosterol

Meds to double-check

Moderate interaction found
Known Interaction Concern · database check
Moderate identified

The most serious documented interaction for these ingredients is Moderate. Check your medications for a personalized result.

Why this rating?
  • 2 of the 3 matched ingredients can interact with medications — Pantethine, Sodium.
  • The most serious interaction on file is rated Moderate.
  • Some involve high-stakes drug classes: anticoagulant / antiplatelet drugs; lithium.
  • For scale: 322 individual medications appear in the full list. A big number alone doesn't make a product dangerous — what matters is whether YOUR medication is on it, so run yours through the interaction checker on this page.

Before you take Cholesterol Shield, check your medications against Moderate-severity interactions with antihypertensive drugs (blood pressure meds), anticoagulant and antiplatelet drugs (blood thinners and clot preventers), corticosteroids, lithium, didanosine, sodium phosphates, tolvaptan, and other sodium-containing drugs. Your own doctor or pharmacist can tell you whether any of your prescriptions are on that list.

Check your own medication Run your meds through the checker above

The bottom line

Scorecard at a glanceFormula with limited ingredient disclosure with some supporting evidence for its stated purpose. Moderate medication interactions have been identified, and safety information is well characterized.

Cholesterol Shield may help with benign prostatic hyperplasia and cholesterol-related conditions, but sodium and pantethine both carry medication interactions you need to check first. If you take blood pressure medications, blood thinners, lithium, corticosteroids, or any other regular prescriptions, confirm with your doctor or pharmacist that this product is safe alongside them.

Not suitable for pregnancy or breastfeeding without medical guidance.

Educational only — not medical advice; always confirm with your pharmacist. Our editorial policy · How we use AI

Assessment coverage: 3 of 7 active ingredients matched to our full ingredient reviews (monographs). Based on the product label dated Jan 25, 2020.

This Scorecard evaluates available label information, ingredient evidence, and known medication-safety considerations. It does not independently verify product identity, purity, potency, contamination, or manufacturing quality. How these ratings are computed

At a glance

General information

Key facts about Cholesterol Shield, straight from the product label.

Brand Nature's Way
Barcode (UPC) 763948055197
Net contents 90 Tablet(s)
Market status On market
Date entered into DSLD Jan 25, 2020
DSLD ID 212298
Product type Other Combinations
Supplement form Tablet Or Pill
Dietary claims / uses Nutrient, All Other, Structure/Function
Intended target group(s) Vegetarian, Adult (18 - 50 Years), Gluten Free, Dairy Free
From the label
Everything in this section is reproduced from the manufacturer’s own product label — it’s the label speaking, not HelloPharmacist. We show it so you can see exactly what the maker states; we don’t verify or endorse those statements.

Supplement Facts

The label details for Cholesterol Shield by Nature's Way, sourced from the NIH Dietary Supplement Label Database.

Supplement Facts

Daily Value (DV) Target Group(s):
Adults and children 4 or more years of age
Minimum serving Sizes:
1 Tablet(s)
Maximum serving Sizes:
1 Tablet(s)
UPC/BARCODE
763948055197
IngredientAmount% DV
Sodium5 mg1%
Stigmasterol0 NP--
Brassicasterol0 NP--
Beta Sitosterol0 NP--
Campesterol0 NP--
Pantesin Pantethine200 mg--
Proprietary Phytosterol Blend400 mg--
other Plant Sterols0 NP--

Other ingredients: Cellulose, Sodium Croscarmellose, Silica, Magnesium Stearate, Hypromellose, Glycerin

Tap any ingredient to jump to its full detail below.

Label statements
These statements are the manufacturer’s wording, reproduced from the product label — the label is saying it, not HelloPharmacist. We don’t verify or endorse them.
Formula

Cholesterol Shield phytosterol blend is a powerful combination of beneficial plant sterols and pantethine, the biologically active form of pantothenic acid. These ingredients have been combined in this formula to: Support healthy cholesterol production Limit absorption of cholesterol from food

Phytosterol blend

Seals/Symbols

Vegetarian

Formulation

Vegetarian

Supports healthy cholesterol levels

Gluten free. No yeast-derived ingredients, wheat, corn, dairy products, or artificial colors, flavors, or preservatives.

In addition to Cholesterol Shield consider these other high-quality supplements within the Heart Matters line: BP Manager proprietary herbal blend - Supports healthy blood pressure levels HDL Assist supplement -Supports good cholesterol (HDL) levels

FDA Disclaimer Statement

These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

General Statements

Since 1969 Heart Matters

Already within normal range

Heart Matters Supplements -A Smart Choice

Your Heart Matters, and So Do You! Each of the three products in the Heart Matters suite of supplements focuses on specific health concerns near and dear to the heart.

FDA Statement of Identity

Dietary Supplement

Suggested/Recommended/Usage/Directions

Recommendation: Take 1 tablet three times daily, with or immediately before each meal.

Precautions

If pregnant, nursing, or taking any medications, consult a healthcare professional before use.

Keep out of reach of children.

Safety sealed with printed inner seal. Do not use if seal is broken or missing.

Brand IP Statement(s)

Pantesin is a registered trademark of Kyowa Pharma Chemical Co., Ltd.

2019 Nature's Way Brands, LLC (previously branded Enzymatic Therapy, LLC)

See for yourself

Cholesterol Shield by Nature's Way label

The label scan from the NIH Dietary Supplement Label Database. Tap to enlarge.

What’s inside

The Ingredients in Cholesterol Shield by Nature's Way

These are the 7 active ingredients this product is made of. Select any to open its full monograph.

Serving size1 Tablet(s) Dosage formTablet Or Pill Amounts shown are per serving.

Most supplement products combine several ingredients, and a medication can interact with the product through any one of them. Each ingredient below shows whether it has known drug interactions.

Sodium

Interacts with
205 drugs
5 mg per serving

Sodium is an essential mineral and electrolyte your body needs to balance fluids, support nerves, and help muscles work. Most people in modern diets g...

Sodium monograph & interactions

Pantesin Pantethine

Interacts with
122 drugs
200 mg per serving

Pantethine is a derivative of vitamin B5 (pantothenic acid) that some studies suggest may modestly lower cholesterol and triglycerides. The evidence i...

Pantesin Pantethine monograph & interactions

Proprietary Phytosterol Blend

400 mg per serving
  • › Stigmasterol
  • › Brassicasterol
  • Beta Sitosterol
  • › Campesterol
  • › Other Plant Sterols

Other (inactive) ingredients: Cellulose, Sodium Croscarmellose, Silica, Magnesium Stearate, Hypromellose, Glycerin. These complete the product’s ingredient list but are not active constituents.

Interaction report

Cholesterol Shield by Nature's Way Drug Interactions

Want to check YOUR meds against Cholesterol Shield?

Ask about interactions with your drugs in plain English — “Can I take it with lisinopril?” — and we find you the answer in seconds, ingredient by ingredient.

Go to the checker
322Drugs
322 Moderate

Ingredients driving the most interactions

Sodium 205

Each ingredient & the kinds of drugs it affects

For each ingredient in Cholesterol Shield with known interactions, here are the types of medications they can affect. Open any type for the detail — or search your exact drug in the checker above.

Sodium7 drug types · 205 drugs

Antihypertensive Drugs

Theoretically, a high intake of dietary sodium might reduce the effectiveness of antihypertensive drugs.
High intake of dietary sodium can increase systolic and diastolic blood pressure. Also, high intake of sodium may necessitate increased use of antihypertensive medications to achieve blood pressure control in some patients, such as those with chronic kidney disease.

Likelihood Probable Evidence A
Corticosteroids

Concomitant use of mineralocorticoids and some glucocorticoids with sodium supplements might increase the risk of hypernatremia.
Mineralocorticoids and some glucocorticoids (corticosteroids) cause sodium retention. This effect is dose-related and depends on mineralocorticoid potency. It is most common with hydrocortisone, cortisone, and fludrocortisone, followed by prednisone and prednisolone.

Likelihood Possible Evidence D
Didanosine (Videx)

Concomitant use of didanosine with additional sodium from dietary or supplemental sources may increase the risk of hypernatremia.
Didanosine formulations contain a significant amount of sodium.

Likelihood Probable Evidence C
Lithium

Altering dietary intake of sodium might alter the levels and clinical effects of lithium.
High sodium intake can reduce plasma concentrations of lithium by increasing lithium excretion. Reducing sodium intake can significantly increase plasma concentrations of lithium and cause lithium toxicity in patients being treated with lithium carbonate. Stabilizing sodium intake is shown to reduce the percentage of patients with lithium level fluctuations above 0.8 mEq/L. Patients taking lithium should avoid significant alterations in their dietary intake of sodium.

Likelihood Probable Evidence B
Sodium Phosphates

Theoretically, concomitant use of sodium phosphate with sodium supplements might increase the risk of hypernatremia.
Use of high doses (> 45 mL in 24 hours) of sodium phosphate, such as those used for bowel cleansing before surgery, can lead to serious electrolyte disturbances, including hypernatremia. The risk of hypernatremia is highest in the elderly and people with other risk factors for electrolyte disturbances.

Likelihood Possible Evidence D
Sodium-Containing Drugs

Concomitant use of sodium-containing drugs with additional sodium from dietary or supplemental sources may increase the risk of hypernatremia and long-term sodium-related complications.
The Chronic Disease Risk Reduction (CDRR) intake level of 2.3 grams of sodium daily indicates the intake at which it is believed that chronic disease risk increases for the apparently healthy population. Some medications contain high quantities of sodium. When used in conjunction with sodium supplements or high-sodium diets, the CDRR may be exceeded. Additionally, concomitant use may increase the risk for hypernatremia; this risk is highest in the elderly and people with other risk factors for electrolyte disturbances.

Likelihood Possible Evidence D
Tolvaptan (Samsca)

Theoretically, concomitant use of tolvaptan with sodium might increase the risk of hypernatremia.
Tolvaptan is a vasopressin receptor 2 antagonist that is used to increase sodium levels in patients with hyponatremia. Patients taking tolvaptan should use caution with the use of sodium salts such as sodium chloride.

Likelihood Probable Evidence C

Pantesin Pantethine1 drug type · 122 drugs

Anticoagulant/Antiplatelet Drugs

Theoretically, pantethine might increase the risk of bleeding with anticoagulant or antiplatelet drugs.
Some evidence suggests that pantethine reduces platelet aggregation.

Likelihood Possible Evidence B
The maker

Brand information

Manufacturer and brand details for Cholesterol Shield, from the product label.

Nature's Way

See all Nature's Way products
Name
Nature's Way Brands, LLC (previously branded Enzymatic Therapy, LLC)
City
Green Bay
State
WI
ZipCode
54311
Phone Number
1-800-962-8873
Web Address
naturesway.com
Pharmacist Counseling Corner

Cholesterol Shield by Nature's Way: Common Questions

Does Cholesterol Shield by Nature's Way interact with any medications?
Yes. Based on its ingredients, Cholesterol Shield has a known interaction with 322 medications. Use the checker to see how it interacts with a specific drug.
How can one product interact with so many drugs?
Cholesterol Shield contains 7 active ingredients, and an interaction can come from any of them. We check every ingredient, combine the results into one list per medication, and show which ingredient and mechanism is responsible.
Where does this information come from?
The product label data comes from the NIH Dietary Supplement Label Database (DSLD); the interaction data is built on the Natural Medicines database and reviewed by HelloPharmacist pharmacists.
Does this product actually work for high cholesterol?
Beta-sitosterol is possibly effective for coronary heart disease and familial hypercholesterolemia, and pantethine is possibly effective for hyperlipoproteinemia — so there's evidence for cholesterol-related benefits. That said, the data we hold don't establish this exact product's effectiveness for general high cholesterol, so talk with your doctor about whether it's right for your situation.
Why does a cholesterol product have sodium in it?
Sodium serves specific therapeutic purposes — it's likely effective for cystic fibrosis and possibly effective for a form of kidney damage caused by certain antifungal drugs. However, if you're taking this product for cholesterol, the sodium is a trade-off: it may interact with your blood pressure or other medications, and excess sodium can strain your heart and kidneys.
What side effects should I expect?
The most common ones are gastrointestinal: constipation, diarrhea, gas, indigestion, nausea, bloating, and flatulence from the phytosterols and pantethine. Beta-sitosterol may worsen acne. Excess sodium can cause high blood pressure and heart or kidney strain — which is why you shouldn't take this without checking your medications first.
Is it safe during pregnancy or while breastfeeding?
No — there isn't enough safety data for pantethine or beta-sitosterol during pregnancy or breastfeeding, and the data for sodium are mixed. Talk with your doctor before taking Cholesterol Shield if you're pregnant, planning to become pregnant, or nursing.
Will this interfere with my blood pressure medication?
Possibly. Sodium can reduce how well blood pressure medications work, especially at high doses. Before you start, check with your doctor or pharmacist — they can tell you if your specific blood pressure drug is affected and whether this product is safe for you.
Can I take this with aspirin or other blood thinners?
The pantethine in this product may theoretically increase bleeding risk with blood thinners (anticoagulants) and anti-clotting drugs like aspirin. Check with your pharmacist or doctor before combining Cholesterol Shield with any blood thinner.

Written and reviewed by the HelloPharmacist editorial staff. Our editorial policy

Not sure if Cholesterol Shield is safe with your meds?

Our pharmacists answer your medication & supplement questions — free.

Ask a pharmacist

Label information is sourced from the NIH Dietary Supplement Label Database and reflects the product version on file; always read your actual product label. This page is for education only and is not a substitute for professional medical advice. Confirm with your pharmacist or doctor before combining supplements and medications.

Cholesterol Shield label
Sources

Sources & How We Checked

Cholesterol Shield's label data comes from the NIH Dietary Supplement Label Database; the ingredient interaction data is from the Natural Medicines database, reviewed by our pharmacists.

Content is written and reviewed by licensed HelloPharmacist pharmacists. See our data sources and editorial standards for how this information is built and checked.

The 54 references behind this product’s interaction data

Every citation that drives the interaction findings for this product’s ingredients, from the evidence-graded Natural Medicines (TRC Healthcare) database. Open an ingredient to browse its citations — links open the study on PubMed or the publisher’s site.

Sodium 38 references
  1. Garabedian-Ruffalo SM, Ruffalo RL. Drug and nutrient interactions. Am Fam Physician 1986;33:165-74.
  2. Food and Drug Administration Science Background: Safety of Sodium Phosphates Oral Solution. September 17, 2001. Available at: http://www.fda.gov/cder/drug/safety/sodiumphospate.htm
  3. Coton T, Mallaret C, Coilliot C, Carre D, Guisset M. Severe acute ulcerated gastritis induced by salt. Presse Med 2009;38(3):499-500. PubMed
  4. Frings-Meuthen P, Buehlmeier J, Baecker N, et al. High sodium chloride intake exacerbates immobilization-induced bone resorption and protein losses. J Appl Physiol 2011;111(2):537-542. PubMed
  5. Frings-Meuthen P, Baecker N, Heer M. Low-grade metabolic acidosis may be the cause of sodium chloride-induced exaggerated bone resorption. J Bone Miner Res 2008;23(4):517-524. PubMed
  6. Alam S, Johnson AG. A meta-analysis of randomised controlled trials (RCT) among healthy normotensive and essential hypertensive elderly patients to determine the effect of high salt (NaCl) diet of blood pressure. J Hum Hypertens 1999;13(6):367-74.
  7. Boudville N, Ward S, Benaroia M, House AA. Increased sodium intake correlates with greater use of antihypertensive agents by subjects with chronic kidney disease. Am J Hypertens 2005;18(10):1300-5. PubMed
  8. Bennett WM. Drug interactions and consequences of sodium restriction. Am J Clin Nutr 1997;65(2 Suppl):678S-681S. PubMed
  9. Okusa MD, Crystal LJ. Clinical manifestations and management of acute lithium intoxication. Am J Med 1994;97(4):383-9. PubMed
  10. Food and Nutrition Board, Institute of Medicine. Dietary reference intakes for water, potassium, sodium, chloride, and sulfate. Washington, DC: National Academy Press, 2005. Available at: http://www.nap.edu/openbook.php?record_id=10925. DOI
  11. D'Elia L, Rossi G, Ippolito R, Cappuccio FP, Strazzullo P. Habitual salt intake and risk of gastric cancer: a meta-analysis of prospective studies. Clin Nutr 2012;31(4):489-98. PubMed
  12. Goldsmith SR. Hyponatremia in heart failure: time for a trial. J Card Fail 2013;19(6):398-400. PubMed
  13. Willocks L, Brettle R, Keen J, Valentine C, Pinching AJ. Formulations of didanosine (ddI) and salt overload. Lancet 1992;339(8786):190.
  14. Chen L, Zhang Z, Chen W, Whelton PK, Appel LJ. Lower Sodium Intake and Risk of Headaches: Results From the Trial of Nonpharmacologic Interventions in the Elderly. Am J Public Health. 2016;106(7):1270-5. PubMed
  15. Cook NR, Appel LJ, Whelton PK. Lower levels of sodium intake and reduced cardiovascular risk. Circulation. 2014;129(9):981-9. PubMed
  16. Cook NR, Appel LJ, Whelton PK. Sodium Intake and All-Cause Mortality Over 20 Years in the Trials of Hypertension Prevention. J Am Coll Cardiol. 2016;68(15):1609-1617. PubMed
  17. Mente A, O'Donnell M, Rangarajan S, et al. Associations of urinary sodium excretion with cardiovascular events in individuals with and without hypertension: a pooled analysis of data from four studies. Lancet. 2016;388(10043):465-75. PubMed
  18. Moosavian SP, Haghighatdoost F, Surkan PJ, Azadbakht L. Salt and obesity: a systematic review and meta-analysis of observational studies. Int J Food Sci Nutr. 2017;68(3):265-277. PubMed
  19. O'Donnell M, Mente A, Rangarajan S, et al. Urinary sodium and potassium excretion, mortality, and cardiovascular events. N Engl J Med. 2014;371(7):612-23. DOI
  20. Poggio R, Gutierrez L, Matta MG, Elorriaga N, Irazola V, Rubinstein A. Daily sodium consumption and CVD mortality in the general population: systematic review and meta-analysis of prospective studies. Public Health Nutr. 2015;18(4):695-704. PubMed
  21. Stallings VA, Harrison M, Oria M; Committee to Review the Dietary Reference Intakes for Sodium and Potassium, Food and Nutrition Board, Health and Medicine Division, National Academies of Sciences, Engineering, and Medicine. Washington (DC): National Acad
  22. Mahtani KR, Heneghan C, Onakpoya I, et al. Reduced Salt Intake for Heart Failure: A Systematic Review. JAMA Intern Med. 2018 Dec 1;178(12):1693-1700. PubMed
  23. Yancy CW. Sodium Restriction in Heart Failure: Too Much Uncertainty-Do the Trials. JAMA Intern Med. 2018 Dec 1;178(12):1700-1701. PubMed
  24. He FJ, Campbell NRC, Ma Y, MacGregor GA, Cogswell ME, Cook NR. Errors in estimating usual sodium intake by the Kawasaki formula alter its relationship with mortality: implications for public health. Int J Epidemiol. 2018;47(6):1784-1795. PubMed
  25. Murthy K, Ondrey GJ, Malkani N, et al. THE EFFECTS OF HYPONATREMIA ON BONE DENSITY AND FRACTURES: A SYSTEMATIC REVIEW AND META-ANALYSIS. Endocr Pract. 2019;25(4):366-378. PubMed
  26. Messerli FH, Hofstetter L, Syrogiannouli L, et al. Sodium intake, life expectancy, and all-cause mortality. Eur Heart J 2021;42(21):2103-2112. PubMed
  27. Graudal NA, Hubeck-Graudal T, Jurgens G. Effects of low sodium diet versus high sodium diet on blood pressure, renin, aldosterone, catecholamines, cholesterol, and triglyceride. Cochrane Database Syst Rev 2020;12(12):CD004022. PubMed
  28. Giatti S, Santos RB, Aielo AN, et al. Association of sodium with obstructive sleep apnea. The ELSA-Brasil study. Ann Am Thorac Soc 2021;18(3):502-510. PubMed
  29. Nan X, Lu H, Wu J, et al. The interactive association between sodium intake, alcohol consumption and hypertension among elderly in northern China: a cross-sectional study. BMC Geriatr 2021;21(1):135. PubMed
  30. Kyozuka H, Fukusda T, Murata T, et al. Impact of preconception sodium intake on hypertensive disorders of pregnancy: The Japan Environment and Children's study. Pregnancy Hypertens 2021;23:66-72. PubMed
  31. Zhao L, Ogden CL, Yang Q, et al. Association of usual sodium intake with obesity among US children and adolescents, NHANES 2009-2016. Obesity (Silver Spring) 2021;29(3):587-594. PubMed
  32. Ma Y, He FJ, Sun Q, et al. 24-Hour urinary sodium and potassium excretion and cardiovascular risk. N Engl J Med 2022;386(3):252-263. PubMed
  33. Liu J, Yang X, Zhang P, et al. Association of urinary sodium excretion and left ventricular hypertrophy in people with type 2 diabetes mellitus: A cross-sectional study. Front Endocrinol (Lausanne) 2021;12:728493. PubMed
  34. Filippini T, Malavolti M, Whelton PK, Vinceti M. Sodium intake and risk of hypertension: A systematic review and dose-response meta-analysis of observational cohort studies. Curr Hypertens Rep 2022;24(5):133-144. PubMed
  35. Wang DD, Li Y, Nguyen XT, et al. Dietary sodium and potassium intake and risk of non-fatal cardiovascular diseases: The million veteran program. Nutrients 2022;14(5):1121. PubMed
  36. Kwak JH, Park CH, Eun CS, et al. The associations of dietary intake of high sodium and low zinc with gastric cancer mortality: A prospective cohort study in Korea. Nutr Cancer 2022;74(10):3501-3508. PubMed
  37. George S, Maiti R, Mishra BR, Jena M, Mohapatra D. Effect of regulated add-on sodium chloride intake on stabilization of serum lithium concentration in bipolar disorder: A randomized controlled trial. Bipolar Disord 2023;25(1):66-75. PubMed
  38. Zhou TL, Schütten MTJ, Kroon AA, et al. Urinary Sodium Excretion and Salt Intake Are Not Associated With Blood Pressure Variability in a White General Population. J Am Heart Assoc 2023;12(1):e026578. PubMed

See these in context on the Sodium monograph →

Beta-sitosterol 7 references
  1. Berges RR, Windeler J, Trampisch HJ, et al. Randomised, placebo-controlled, double-blind clinical trial of beta-sitosterol in patients with benign prostatic hyperplasia. Beta-sitosterol Study Group. Lancet 1995;345:1529-32.
  2. Klippel KF, Hiltl DM, Schipp B. A multicentric, placebo-controlled, double-blind clinical trial of beta-sitosterol (phytosterol) for the treatment of benign prostatic hyperplasia. Br J Urol 1997;80:427-32.
  3. Wilt TJ, MacDonald R, Ishani A. beta-sitosterol for the treatment of benign prostatic hyperplasia: a systematic review. BJU Int 1999;83:976-83. PubMed
  4. Oster P, Schlierf G, Heuck CC, et al. [Sitosterol in familial hyperlipoproteinemia type II. A randomized, double-blind, cross-over study]. Dtsch Med Wochenschr 1976;101:1308-11.
  5. Becker M, Staab D, Von Bergman K. Long-term treatment of severe familial hypercholesterolemia in children: effect of sitosterol and bezafibrate. Pediatrics 1992;89:138-42. DOI
  6. Prager N, Bickett K, French N, Marcovici G. A randomized, double-blind, placebo-controlled trial to determine the effectiveness of botanically derived inhibitors of 5-alpha-reductase in the treatment of androgenetic alopecia. J Altern Complement Med 2002
  7. Lorenze A, Hsueh W, Nasr J. Beta-sitosterol-induced acute pancreatitis: A case report and review of the literature. Cureus. 2020;12(3):e7407. PubMed

See these in context on the Beta-sitosterol monograph →

Pantethine 9 references
  1. Da Col PG, Cattin L, Fonda M, et al. Pantethine in the treatment of hypercholesterolemia: a randomized double-blind trial versus tiadenol. Curr Ther Res 1984;36:314-22.
  2. Rubba P, Postaiglione B, De Simone F, et al. Comparative evaluation of the lipid-lowering effects of fenofibrate and pantethine in type II hyperlipoproteinemia. Curr Ther Res 1985;38:719-27.
  3. Coronel F, Tornero F, Torrente J, et al. Treatment of hyperlipemia in diabetic patients on dialysis with a physiological substance. Am J Nephrol 1991;11:32-6.. PubMed
  4. Agrati AM, Ambrosi G, Ferraro G, Palmieri. Gemfibrozil efficacy vs pantethine in dyslipoproteinemic patients: a controlled study. Curr Ther Res 1989;45:650-63.
  5. Rumberger, J. A., Napolitano, J., Azumano, I., Kamiya, T., and Evans, M. Pantethine, a derivative of vitamin B(5) used as a nutritional supplement, favorably alters low-density lipoprotein cholesterol metabolism in low- to moderate-cardiovascular risk No
  6. Hiramatsu, K., Nozaki, H., and Arimori, S. Influence of pantethine on platelet volume, microviscosity, lipid composition and functions in diabetes mellitus with hyperlipidemia. Tokai J.Exp.Clin.Med. 1981;6(1):49-57.
  7. McRae MP. Treatment of hyperlipoproteinemia with pantethine: A review and analysis of efficacy and tolerability. Nutrition Res 2005;25:319-333. DOI
  8. Cattin, L., Da Col, P. G., Fonda, M., Mameli, M. G., and Fergulio, G. A. Treatment of hypercholesterolemia with pantethine and fenofibrate; open randomized study on 43 subjects. Current Therapeutic Research 1985;38(Sep):386-395.
  9. Evans M, Rumberger JA, Azumano I, Napolitano JJ, Citrolo D, Kamiya T. Pantethine, a derivative of vitamin B5, favorably alters total, LDL and non-HDL cholesterol in low to moderate cardiovascular risk subjects eligible for statin therapy: a triple-blinded

See these in context on the Pantethine monograph →

Parts of this content are provided by the Therapeutic Research Center, LLC.

DISCLAIMER: Currently this does not check for drug-drug interactions. This is not an all-inclusive comprehensive list of potential interactions and is for informational purposes only. Not all interactions are known or well-reported in the scientific literature, and new interactions are continually being reported. Input is needed from a qualified healthcare provider including a pharmacist before starting any therapy. Application of clinical judgment is necessary.

© 2021 Therapeutic Research Center, LLC

Keep exploring